Company Focus
CSL Limited.
Latest CSL Limited. News
Biotechnology
Global biotechnology firm CSL Behring has announced that two patients with hemophilia B have been treated with the gene therapy Hemgenix (etranacogene dezaparvovec). 5 July 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to CSL Limited.
Biotechnology
Cambridge, UK-based clinical-stage biotech CellCentric has appointed Andy Fergus as chief development officer. 5 September 2024
Pharmaceutical
Lausanne-based Haya Therapeutics has entered into a multi-year agreement with Eli Lilly focused on obesity and related metabolic conditions. 5 September 2024
Pharmaceutical
Lexicon Pharmaceuticals yesterday announced that a post-hoc analysis of Phase III data from the SCORED clinical trial demonstrated that Inpefa (sotagliflozin) reduced the risk of major adverse cardiovascular events. 4 September 2024
Biotechnology
Valneva and US pharma giant Pfizer announced positive immunogenicity and safety data from their VLA15-221 Phase II study. 4 September 2024
Pharmaceutical
US metabolic health company Skye Bioscience has announced the appointment of Puneet Arora as chief medical officer (CMO). 3 September 2024
Biotechnology
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
Biotechnology
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) continues to evolve with the introduction of new therapies. 3 September 2024
Pharmaceutical
California, USA-based vaccine developer Vaxcyte saw its shares leap almost 33% to $107.12 in pre-market activity as it revealed very impressive early-stage trial results. 3 September 2024
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized mRNA specialist Moderna’s updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. 3 September 2024
Biotechnology
Anthos Therapeutics has reported a new analysis from the landmark AZALEA-TIMI 71 study, demonstrated that the investigational Factor XI inhibitor abelacimab was associated with remarkably low levels of periprocedural bleeding in patients with atrial fibrillation (AFib). 3 September 2024
Latest In Brief for CSL Limited.
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
30 October 2024
26 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze